Naloxone

Introduction Overview

Generic Name

Naloxone

Brand Name

Narcan, Rezenopy, Kloxxado, Zimhi

Dosage Form

Injectable solution (Zimhi 5 mg/0.5 mL), Nasal spray (Narcan 4 mg, Rezenopy 10 mg, Kloxxado 8 mg)

Drug Class

Antidotes

Pharmacokinetics

Absorption:
Naloxone can be administered via intravenous (IV), intramuscular (IM), subcutaneous (SC), or intranasal routes, with bioavailability and onset of action varying accordingly. The IV route offers the fastest absorption and clinical effect, typically within 2 minutes, making it preferred in emergency settings. Intramuscular and subcutaneous administration yield bioavailabilities of approximately 35-50%, with onset of action within 2 to 5 minutes. Intranasal absorption depends on the formulation and device but generally achieves rapid systemic absorption with onset around 2 to 3 minutes. Factors influencing absorption include nasal mucosa condition for intranasal delivery and muscle perfusion for injectable routes.

Distribution:
Naloxone is distributed rapidly throughout the body tissues after administration. It crosses the blood-brain barrier quickly to reach central opioid receptors, which accounts for its ability to reverse CNS opioid effects effectively. The volume of distribution is relatively large (~1.1 L/kg), indicating extensive tissue binding. Protein binding is low to moderate, allowing efficient receptor occupancy. Distribution kinetics support the rapid onset and offset of naloxone's clinical action.

Metabolism:
Naloxone undergoes extensive hepatic metabolism primarily via glucuronidation to naloxone-3-glucuronide, an inactive metabolite. Cytochrome P450 enzymes have minimal involvement, reducing variability due to enzyme inducers or inhibitors. The metabolic process reduces active drug concentration, contributing to the relatively short duration of action. Liver impairment may affect clearance but naloxone’s short half-life remains clinically adequate in most patients.

Elimination:
Naloxone and its metabolites are eliminated mainly by renal excretion. The elimination half-life ranges between approximately 30 to 81 minutes depending on the route and patient factors. Due to naloxone’s shorter half-life compared to many opioids, repeated dosing or continuous infusion may be required to maintain opioid antagonism after overdose reversal. Dose adjustments are generally not recommended but monitoring is essential if renal impairment is present. The rapid elimination underscores the need for emergency medical supervision after naloxone administration.

Dosage Forms

Available Dosage Forms:
- Injectable solution (Zimhi): 5 mg/0.5 mL single-dose auto-injector
- Nasal sprays:
- Narcan: 4 mg per spray, single-dose nasal spray device
- Rezenopy: 10 mg per spray, single-dose nasal spray
- Kloxxado: 8 mg per spray, single-dose nasal spray

Dosages for Adults and Adolescents:
- Opioid overdose reversal:
- IV, IM, or SC: Initial dose of 0.4 mg to 2 mg; repeat every 2-3 minutes as needed
- Auto-injector (IM/SC): 0.4 mg per actuation; repeat doses every 2-3 minutes until emergency help arrives
- Nasal spray: One spray (Narcan 4 mg or equivalent) into one nostril; if needed, repeat every 2-3 minutes alternating nostrils
- Reversal of opioid sedation:
- IV: 0.1 to 0.2 mg every 2-3 minutes titrated to desired effect
- Supplemental IM doses for longer-lasting effects
- Pediatric dosing:
- Neonates: 0.01 mg/kg IV, IM, or SC; repeat every 2-3 minutes as needed
- Children: 0.01 mg/kg IV initially, up to 0.1 mg/kg IV if needed; or 0.4 mg IM/SC via auto-injector with repeats similarly timed
- Special care with infants under 1 year: pinch thigh muscle during injection

Specific Patient Populations:
- Neonates require weight-based dosing with careful titration to avoid severe withdrawal
- Patients with renal or hepatic impairment require close monitoring though no formal dose adjustments established
- Pregnant patients: use is warranted despite risk of precipitating fetal opioid withdrawal due to life-threatening nature of overdose
- Repeat dosing often necessary in patients exposed to long-acting opioids due to naloxone’s shorter half-life
- Auto-injectors and nasal sprays are designed for ease of use by caregivers and laypersons in emergency overdose situations

Mechanism Of Action

Naloxone is a pure opioid antagonist that exerts its clinical effects by competitively binding opioid receptors, particularly the mu-opioid receptors (MOR), in the central nervous system. It exhibits the highest affinity for mu receptors but can also bind to kappa and delta opioid receptor subtypes with lower affinity. By occupying these receptors without activating them, naloxone effectively blocks and reverses the pharmacologic effects of opioid agonists such as morphine, heroin, fentanyl, and others.

At the molecular level, naloxone's antagonism displaces opioid molecules from the receptors, which leads to rapid reversal of opioid-induced respiratory depression, sedation, and analgesia. Cellularly, this antagonism restores normal neurotransmitter activity, particularly reversing the opioid-mediated inhibition of neurons controlling respiration. The blockade prevents the inhibitory effects opioids typically induce on neuronal excitability and neurotransmitter release.

Biochemically, naloxone does not activate opioid receptors and therefore does not produce opioid-like effects or euphoria, nor does it cause dependence or withdrawal symptoms by itself. However, in opioid-dependent individuals, naloxone administration can precipitate acute withdrawal by rapidly reversing opioid receptor activation. This is clinically significant for titrating doses during overdose reversal to avoid severe withdrawal reactions.

Clinical studies have demonstrated naloxone’s capacity to rapidly restore adequate ventilation and consciousness in overdosed patients, reducing morbidity and mortality associated with opioid poisoning. Compared with other opioid antagonists like naltrexone or nalmefene, naloxone is favored because of its rapid onset, relatively short duration, and safety profile in emergency rescue. Extensive clinical usage and approval of various delivery systems, including injectable and intranasal forms, underscore naloxone’s crucial role in opioid emergency management and harm reduction strategies worldwide.

Pharmacological Actions

Competitive antagonist at opioid mu receptors reversing opioid effects
Blocks opioid-induced respiratory depression and sedation
Does not activate opioid receptors or produce analgesia
Precipitates withdrawal symptoms in opioid-dependent individuals
Restores normal respiratory and CNS function after opioid overdose
Rapid onset of action with intravenous administration
Intermediate duration of action requiring possible repeat dosing
Reverses effects of both endogenous and exogenous opioids
Useful in diagnostic differentiation of opioid overdose vs other CNS depressants
Does not cross-activate kappa or delta opioid receptor subtypes significantly
Minimal intrinsic activity, leading to high safety profile
Facilitates emergency management of opioid toxicity
Used as an antidote in multi-ingredient opioid addiction treatment medications
Non-addictive and non-scheduled substance

Therapeutic Or Clinical Uses

Emergency treatment of known or suspected opioid overdose in adults and children
Rapid reversal of opioid-induced respiratory depression and sedation
Diagnostic tool in suspected opioid toxicity
Used in neonatal opioid withdrawal syndrome management with caution and protocols
Component of multi-ingredient formulations for opioid addiction treatment (e.g., buprenorphine/naloxone)
Adjunct in opioid reversal during surgical anesthesia to titrate sedation levels
Prevention of opioid overdose fatalities in community and healthcare settings
Available as an over-the-counter medication (nasal spray forms) to improve access in emergencies
Emergency rescue medication for patients prescribed opioids at risk of overdose
Harm reduction agent distributed via public health programs and syringe exchanges
Used in combination with oxycodone in formulations to decrease abuse potential
Treatment of opioid overdose from both illicit and prescribed opioids
Supportive therapy requiring additional medical and respiratory support after administration
Utilized by caregivers, emergency personnel, and laypersons for timely overdose intervention

Side Or Adverse Effects

Sudden onset of opioid withdrawal symptoms including nausea, vomiting, and diarrhea
Fever, sweating, body aches, and general weakness after administration
Tremors, shivering, and restlessness; feeling nervous or irritable
Fast heart rate (tachycardia) and increased blood pressure
Goosebumps, yawning, and runny nose indicative of withdrawal
Rare allergic reactions including hives, swelling, and difficulty breathing
Injection site reactions such as pain or irritation with injectable forms
Potential for pulmonary edema in rare overdose reversal cases
Possible headache or dizziness following administration
Patients may experience transient reversal of pain relief causing distress
In neonates, risk of severe withdrawal with symptoms like stiffness and seizures
No reported addiction or dependency with naloxone use
Rapid opioid reversal can precipitate acute withdrawal syndrome in dependent patients
Minimal adverse effects when used appropriately under emergency conditions

Precautions

Ensure emergency medical care is sought immediately after naloxone administration
Use cautiously in patients with known cardiovascular disease due to possible sympathetic activation
Inform healthcare providers of naloxone use, especially during pregnancy or breastfeeding
Patients using long-acting opioids may require repeated doses due to naloxone’s shorter half-life
Avoid leaving treated individuals alone after dosing due to risk of relapse into respiratory depression
Educate caregivers and family members on proper use and emergency procedures
Use caution in neonates to avoid precipitating life-threatening withdrawal
Alcohol use may exacerbate some side effects of naloxone
Monitor blood pressure and heart rate during reversal therapy to manage potential reactions
Pregnant women should receive naloxone for overdose despite fetal withdrawal risk due to maternal benefit
Take care to use weight-based dosing and titration in pediatric populations
Store naloxone properly to maintain drug stability and efficacy
Patients with renal or hepatic dysfunction should be closely monitored
Avoid repeated or excessive dosing to prevent unnecessary withdrawal symptoms

Warnings

Naloxone administration requires prompt follow-up with emergency medical services
May precipitate severe opioid withdrawal syndrome that can be distressing and dangerous
Use of naloxone does not replace comprehensive addiction treatment or overdose prevention
Not effective for non-opioid drug overdoses
Improper use or delayed administration can result in fatal outcomes
Naloxone’s duration may be shorter than certain opioids requiring multiple doses
Use in pregnant women can cause fetal opioid withdrawal; however, overdose treatment benefits outweigh risks
Possible impairment of thinking or reactions after administration; caution with driving or machinery
Patients should be observed for recurrence of opioid toxicity symptoms after initial reversal
Risk of pulmonary edema has been reported rarely after rapid opioid reversal
Potential hypersensitivity reactions require immediate medical attention
Should not be used to treat respiratory depression due to non-opioid causes
Emergency caregivers must be informed of naloxone administration during ongoing management
Avoid leaving a patient untreated or unattended after opiate antagonism

Contraindication

Known hypersensitivity or allergy to naloxone or any component of the formulation
Not intended for treatment of respiratory depression not caused by opioids
Use with caution in individuals without clear evidence of opioid overdose
Not contraindicated in pregnancy when used for emergency opioid overdose reversal
Avoid repeated doses without medical supervision due to withdrawal risks
Contraindicated for use as a pain management agent or in opioid addiction without proper formulation
Not suitable for use in non-opioid-induced CNS or respiratory depression
Contraindicated in patients with nasal injury or obstruction for intranasal administration without physician guidance
Avoid use in patients with severe cardiovascular disease without careful monitoring
No known absolute contraindications beyond hypersensitivity

Drug Interactions

No clinically significant drug interactions due to naloxone’s pharmacologic profile
May antagonize therapeutic opioid analgesics leading to loss of pain control
Concurrent use with opioid agonists will necessitate repeated naloxone dosing
No major interactions with common prescription or OTC medications reported
No known interactions with vitamins or herbal supplements
Naloxone may reverse sedation effects of opioids used during anesthesia requiring supplemental dosing
Use caution when co-administered with drugs that affect respiratory drive
No effect on drug metabolism enzymes minimizing interaction potential
No known interactions with other antidotes or emergency medications
Concomitant opioid withdrawal induced by naloxone may alter pharmacodynamics of other CNS agents
No interaction with coagulation or cardiovascular drugs
Potential interaction with opioid replacement therapies necessitates careful clinical monitoring
May interfere with opioid-dependent diagnostic tests if administered
Drug interactions primarily related to opioid antagonism, not direct pharmacokinetic effects

Preparations Of The Drug

Kloxxado nasal spray containing naloxone hydrochloride 8 mg per single-use device; inactive ingredients include dehydrated alcohol, edetate disodium dihydrate, propylene glycol
Narcan nasal spray with 4 mg naloxone hydrochloride per spray; preservatives include benzalkonium chloride and disodium EDTA
Rezenopy nasal spray delivering 10 mg naloxone hydrochloride; contains glycerin, trisodium citrate dihydrate, and pH adjusters
Zimhi injectable auto-injector containing 5 mg naloxone hydrochloride in 0.5 mL solution; inactive ingredients are sodium chloride and pH adjusters
Auto-injectors designed for ease of intramuscular administration through clothing
Nasal sprays formulated for single-dose administration with no reuse capability
Preservative systems selected to maintain stability and safety for intranasal use
Deliveries designed for rapid bioavailability and immediate clinical effect
Packaging includes protective cases or boxes to protect from light and temperature extremes
Formulations devoid of natural rubber latex to reduce allergenic potential
Designed to be stable at room temperature with specific storage recommendations
Available as prescription and, for Narcan nasal spray, as over-the-counter product
Diluent and pH adjustment to optimize absorption and minimize irritation
Manufactured and distributed by specialized pharmaceutical companies with established quality controls